LONDON BROKER RATINGS: Deutsche Bank cuts Direct Line to 'hold'
13th Jan 2025 09:37
(Alliance News) - The following London-listed shares received analyst recommendations on Monday morning and on Friday: Read More
(Alliance News) - The following London-listed shares received analyst recommendations on Monday morning and on Friday: Read More
(Alliance News) - AstraZeneca PLC on Monday said its lung cancer treatment, co-developed with Daiichi Sankyo Co Ltd, is under priority review for approval by the US Food & Drug Administration. Read More
(Alliance News) - Patients in England with a form of breast cancer will be offered a new treatment after it was given the green light for NHS use. Read More
(Alliance News) - Hutchmed (China) Ltd on Thursday said it has agreed to divest a 45% stake in Shanghai Hutchison Pharmaceuticals Ltd to GP Health Service Capital Co Ltd and Shanghai Pharmaceuticals Holding Co Ltd, for a total of around USD608 million. Read More
(Alliance News) - Stock prices in London were mostly lower at midday on Friday as market participants continue digesting US jobless data and unrest in Mozambique puts miners on edge. Read More
(Alliance News) - Syncona Ltd on Friday said one of its investments Achilles Therapeutics PLC has sold its technology assets to AstraZeneca PLC for USD12 million. Read More
(Alliance News) - The FTSE 100 index in London was called slightly lower on Friday, as investors digest holiday-season sales results in the US and UK. Read More
(Alliance News) - Stock prices in London opened higher on Tuesday, injecting some festive cheer into proceedings as markets prepare to close early on Christmas Eve. Read More
(Alliance News) - AstraZeneca PLC and its Japanese partner Daiichi-Sankyo Co Ltd have withdrawn an application in the European Union for datopotamab deruxtecan for treating certain forms of non-small cell lung cancer. Read More
(Alliance News) - Stocks were called to open in the green on Monday, as markets prepare to close early on Christmas Eve. Read More
(Alliance News) - Blue chips picked up in late trading to close higher on Monday, but mid-caps faltered as investors assessed a raft of downbeat domestic economic data. Read More
(Alliance News) - London's FTSE 100 recouped early losses to trade just in the green at midday on Monday although a raft of gloomy economic reports provided little festive cheer. Read More
(Alliance News) - AstraZeneca PLC on Monday said it has received approval in the European Union for Tagrisso, its non-small cell lung cancer treatment. Read More
(Alliance News) - Stocks in London were called to open down on Monday morning, as investors digest some unwelcome UK economic news at the start of a holiday-shortened week. Read More
(Alliance News) - Sales in China have suffered for AstraZeneca PLC after the arrest of its country president, the Financial Times reported on Wednesday, citing "two people familiar with the matter". Read More
(Alliance News) - Stock prices in London opened mostly lower on Monday, following another disappointing data release from China. Read More
Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical firm - Is to receive a USD10 million milestone payment from partner Takeda Pharmaceutical Co Ltd. Takeda receives a national reimbursement recommendation for the Fruzaqla cancer treatment in Spain this month. It is the first national reimbursement recommendation in Europe for the drug. "We are delighted for both our partner, Takeda, and patients in Spain who will now be able to receive reimbursement for this innovative treatment. This is an important step forward in improving patient access across Europe more broadly," Hutchmed Chief Executive Officer Weiguo Su says. "It also underscores our ongoing collaboration with Takeda and reinforces our shared commitment to addressing the needs of patients with metastatic colorectal cancer." Read More
Merck & Co Inc and AstraZeneca PLC - Rahway, New Jersey and Cambridge, England-based pharmaceutical firms - Report positive long-term results from phase three OlympiA trial on the use of Lynparza, generic name olaparib, to treat germline BRCA-mutated HER2-negative high-risk early breast cancer. Data showed clinically meaningful improvements in overall survival; invasive disease-free survival and distant disease-free survival, a decrease in the rate of cancer returning and spreading to other organs. After six years, OS rate was 87.5% compared to 83.2% in the placebo group, IDFS rate was 79.6% compared to 70.3% in placebo and DDFS was 83.5% compared to 75.7% in placebo. Lynparza is being jointly developed and commercialized by AstraZeneca and Merck and has been approved in the US, EU and Japan, among others. The EU indication also includes patients with locally advanced breast cancer. Read More
(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday announced they have been granted a breakthrough therapy designation in the US to treat some sufferers of non-small cell lung cancer. Read More
(Alliance News) - London's FTSE 100 is called higher, while stocks in Hong Kong perked up amid after a slow start amid fresh hope for the Chinese economy. Read More